MA46652A - Polythérapie pour l'inhibition de c3 - Google Patents

Polythérapie pour l'inhibition de c3

Info

Publication number
MA46652A
MA46652A MA046652A MA46652A MA46652A MA 46652 A MA46652 A MA 46652A MA 046652 A MA046652 A MA 046652A MA 46652 A MA46652 A MA 46652A MA 46652 A MA46652 A MA 46652A
Authority
MA
Morocco
Prior art keywords
polytherapy
inhibition
Prior art date
Application number
MA046652A
Other languages
English (en)
Inventor
Cedric Francois
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of MA46652A publication Critical patent/MA46652A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
MA046652A 2016-10-17 2017-10-16 Polythérapie pour l'inhibition de c3 MA46652A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662409357P 2016-10-17 2016-10-17

Publications (1)

Publication Number Publication Date
MA46652A true MA46652A (fr) 2019-08-21

Family

ID=62019501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046652A MA46652A (fr) 2016-10-17 2017-10-16 Polythérapie pour l'inhibition de c3

Country Status (12)

Country Link
US (2) US11338013B2 (fr)
EP (1) EP3526328A4 (fr)
JP (2) JP2020500157A (fr)
CN (2) CN110249053A (fr)
AU (1) AU2017346486B2 (fr)
BR (1) BR112019007613A2 (fr)
CA (1) CA3040917A1 (fr)
IL (1) IL266012B2 (fr)
MA (1) MA46652A (fr)
MX (1) MX2019004500A (fr)
RU (1) RU2019113301A (fr)
WO (1) WO2018075373A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CA3287719A1 (en) 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
EP3526328A4 (fr) 2016-10-17 2020-05-27 Apellis Pharmaceuticals, Inc. Polythérapie pour l'inhibition de c3
WO2018085208A1 (fr) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Procédés d'inhibition de virus à l'aide de compositions ciblant l'interaction tsg101-ubiquitine
CN116059313A (zh) * 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
US11866701B2 (en) * 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP3790970A1 (fr) 2018-05-07 2021-03-17 Alnylam Pharmaceuticals Inc. Administration extra-hépatique
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症1型および関連状態を治療する方法
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
US20220195436A1 (en) * 2019-08-27 2022-06-23 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
BR112022007540A2 (pt) 2019-10-22 2022-07-12 Alnylam Pharmaceuticals Inc Composições de irna de componente complementar c3 e métodos de uso das mesmas
KR20220115579A (ko) * 2019-12-06 2022-08-17 서나오믹스, 인크. 표적화된 핵산 전달을 위한 펩티드 도킹 비히클
AU2021221035A1 (en) * 2020-02-14 2022-09-08 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
MX2023002673A (es) 2020-09-04 2023-05-12 Alexion Pharma Inc Métodos para el tratamiento de trastornos de mineralización ósea.
IL307721A (en) * 2021-04-20 2023-12-01 Astrazeneca Ireland Ltd Compounds and methods for inhibiting expression of component 3
WO2022251484A1 (fr) * 2021-05-26 2022-12-01 Apellis Pharmaceuticals, Inc. Traitement de troubles à médiation par le complément
WO2022251409A2 (fr) * 2021-05-27 2022-12-01 Apellis Pharmaceuticals, Inc. Édition génomique du complément
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
JP2024035932A (ja) * 2022-09-05 2024-03-15 株式会社島津製作所 イオンクロマトグラフィ分析システム
US12110492B2 (en) 2022-10-27 2024-10-08 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188239B (zh) 2005-11-28 2020-01-07 宾夕法尼亚州大学理事会 有效的坎普他汀类似物
US20070178068A1 (en) * 2005-12-22 2007-08-02 Reich Samuel J Compositions and methods for regulating complement system
WO2009121065A2 (fr) * 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
CA2835627C (fr) * 2011-05-11 2023-01-10 Apellis Pharmaceuticals, Inc. Analogues de la compstatine cibles, a longue duree d'action, reactifs aux cellules, et leurs utilisations
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
EP3929206A1 (fr) * 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Analogues de la compstatine à longue durée d'action et compositions et méthodes associées
US10308687B2 (en) * 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA2931090A1 (fr) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Composition d'arni d'element de complement et procedes pour les utiliser
EP3526328A4 (fr) 2016-10-17 2020-05-27 Apellis Pharmaceuticals, Inc. Polythérapie pour l'inhibition de c3
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof

Also Published As

Publication number Publication date
CN118217402A (zh) 2024-06-21
RU2019113301A3 (fr) 2021-02-20
CN110249053A (zh) 2019-09-17
IL266012B1 (en) 2024-05-01
RU2019113301A (ru) 2020-11-17
BR112019007613A2 (pt) 2019-07-02
US20230009757A1 (en) 2023-01-12
AU2017346486A1 (en) 2019-05-23
JP2020500157A (ja) 2020-01-09
MX2019004500A (es) 2019-08-21
AU2017346486B2 (en) 2024-06-13
WO2018075373A1 (fr) 2018-04-26
CA3040917A1 (fr) 2018-04-26
EP3526328A4 (fr) 2020-05-27
US11338013B2 (en) 2022-05-24
JP2022188048A (ja) 2022-12-20
EP3526328A1 (fr) 2019-08-21
IL266012B2 (en) 2024-09-01
US20200282012A1 (en) 2020-09-10
IL266012A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3446194A4 (fr) Raccourcis d'application pour carplay
EP3649610A4 (fr) Agencement d'emplacements d'arrêt pour des véhicules autonomes
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
EP3324840A4 (fr) Tensiomètre pour l'estimation de débit
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
EP3430731A4 (fr) Architecture d'iugw
EP3347458A4 (fr) Cochon multi-transgénique pour xénogreffe
EP3337587A4 (fr) Distributeur d'eau
EP3314205A4 (fr) Technologies pour navigation à l'estime pour piéton
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3277757A4 (fr) Compositions pour l'inhibition de corrosion
EP3365403A4 (fr) Combinaison d'inhibiteurs de cobalt pour un bombage amélioré
MA49006A (fr) Inhibiteurs d'ip6k
EP3627918C0 (fr) Radiorecherche d'extension de couverture pour ec-gsm
EP3397288A4 (fr) Méthodes pour diminuer l'expression de l'ataxine-2
MA39500A (fr) Compositions à base d'extraits de plantes pour l'inhibition de la 5-alpha-réductase
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3431808A4 (fr) Butée d'arrêt
EP3500898A4 (fr) Hélage d'un véhicule
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire